Cancer - BeiGene, Ltd.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05006716

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

Drug

BGB-16673

Condition

Patients With B-Cell Malignancies